Mirna Therapeutics Inc (MIRN) was Downgraded by H.C. Wainwright to ” Neutral” while Lowering the Price Target of the company shares to $ 2 from a previous price target of $6 . Earlier the firm had a rating of “Buy ” on the company shares. H.C. Wainwright advised their investors in a research report released on Sep 23, 2016.
Many Wall Street Analysts have commented on Mirna Therapeutics Inc. Mirna Therapeutics Inc was Downgraded by Cantor Fitzgerald to ” Hold” on Sep 21, 2016. H.C. Wainwright Initiated Mirna Therapeutics Inc on Sep 12, 2016 to “Buy”, Price Target of the shares are set at $6.Mirna Therapeutics Inc was Downgraded by Citigroup to ” Neutral” on Aug 17, 2016.
Mirna Therapeutics Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy microRNA Replacement Therapy focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics. Its pipeline of products includes MRX34 miR-101 miR-215 let-7 and miR-16. The Company’s lead product candidate MRX34 a mimic of naturally occurring microRNA-34 (miR-34) is in Phase I clinical trial in patients with primary liver cancer advanced solid tumors and hematological malignancies. Its miR-34 is considered a key regulator of multiple oncogenes across key oncogenic pathways. The Company focuses on developing MRX34 as a monotherapy and in combination with other therapeutic modalities such as targeted therapies and immuno-oncology agents.